New NICE Guideline for Type 2 Diabetes Recognises Benefits From Newer Agents for Blood Glucose Control
London (ots/PRNewswire) - - For Healthcare and Pharmaceutical Correspondents Only - NICE Recommends Considering DPP-4 Inhibitors as a Second Line Treatment Option in Appropriate Patients Merck Sharp & Dohme Limited (MSD) welcomes the publication of the guideline for type 2 diabetes newer agents1 from ...
mehr